Table 1.
Characteristics at enrollment of the 847 participants who progressed to ESRD during follow up.
| Characteristic | Values |
|---|---|
| Age, years | 55.5 ± 11.6 |
| Female, % | 40.0 |
| Black, % | 52.3 |
| Hispanic, % | 17.4 |
| Current smoking, % | 16.3 |
| BMI, kg/m2 | 32.6 ± 8.2 |
| SBP, mmHg | 138.6 ± 24.0 |
| Hypertension, % | 93.7 |
| Diabetes, % | 65.4 |
| Heart failure, % | 12.9 |
| Stroke, % | 11.3 |
| Peripheral vascular disease, % | 9.8 |
| Coronary artery disease, % | 23.9 |
| Phosphate binder use (%) | 8.0 |
| Nutritional vitamin D use (%) | 7.7 |
| Active vitamin D use (%) | 5.2 |
| eGFR, ml/min/1.73m2 | 33.9 ± 11.1 |
| UACR, mg/g | 786.3 (232.9 – 1978.3) |
| Hemoglobin, g/dL | 11.9 ± 1.8 |
| Serum albumin, g/dL | 3.7 ± 0.5 |
| Calcium, mg/dL | 9.0 ± 0.5 |
| Phosphate, mg/dL | 4.0 ± 0.8 |
| PTH, pg/mL | 88.0 (52.0 – 144.1) |
| FGF-23, RU/mL | 207.2 (140.9 – 334.7) |
Values are means ± standard deviation (SD), medians [interquartile range].
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; UACR, urine albumin-creatinine ratio; PTH, parathyroid hormone; FGF-23, fibroblast growth factor 23; RU, reference units.